Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Phase I-II Study of Fludarabine, Cytarabine and Oxaliplatin In Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Apostolia Maria Tsimberidou, MD, PhD, Michael J Keating, MD, Elihu H. Estey, MD, Elias Jabbour, Patrick Zweidler-McKay, MD, PhD, William Plunkett, PhD, Hagop M Kantarjian, Gautam Borthakur

Blood (2011) 118 (21): 4274.

https://doi.org/10.1182/blood.V118.21.4274.4274

Published: 2011

Journal Articles

Results of a Phase I-II Clinical Trial of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab (OFAR) Combination Therapy In Patients with Aggressive, Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Richter Syndrome (RS)

Apostolia Maria Tsimberidou, MD, PhD, William G. Wierda, MD, PhD, Sijin Wen, Ph.D., William Plunkett, PhD, Susan O'Brien, MD, Thomas J. Kipps, MD, PhD, Jeffrey A. Jones, MD, MPH, Hagop M. Kantarjian, Michael J. Keating, MD

Blood (2010) 116 (21): 923.

https://doi.org/10.1182/blood.V116.21.923.923

Published: 2010

Journal Articles

Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy Induces High Response Rates in Agressive Chronic Lymphocytic Leukemia (CLL) and Richter's Syndrome (RS).

Apostolia-Maria Tsimberidou, MD, PhD, William Wierda, MD, PhD, William Plunkett, Susan O'Brien, M.D., Thomas J. Kipps, MD, PhD, Jeffrey Alan Jones, MD, MPH, Susan Smith, Annette Jalayer, RN, Hagop M. Kantarjian, MD, Michael Keating, MD

Blood (2009) 114 (22): 3443.

https://doi.org/10.1182/blood.V114.22.3443.3443

Published: 2009

Journal Articles

Pediatric Therapy-Related Myelodysplastic Syndrome/Acute Myeloid Leukemia: The M. D. Anderson Cancer Center Experience

Dolly G Aguilera, Christos Vaklavas, MD, Apostolia-Maria Tsimberidou, MD, PhD, Sijin Wen, PhD, L. Jeffrey Medeiros, MD, Seth J. Corey

Blood (2008) 112 (11): 5068.

https://doi.org/10.1182/blood.V112.11.5068.5068

Published: 2008

Journal Articles

Clinical Outcomes and Factors Predicting Development of Venous Thromboembolic Complications in Patients with Advanced Refractory Cancer in a Phase I Clinic: The M. D. Anderson Cancer Center Experience

Apostolia-Maria Tsimberidou, MD, PhD, Sushma Vemulapalli, MD, Lakshmi Chintala, MD, Navjot Dhillon, MD, Xiudong Lei, PhD, David Hong, MD, Razelle Kurzrock, MD, Investigational Cancer Therapeutics, M.D.

Blood (2008) 112 (11): 3828.

https://doi.org/10.1182/blood.V112.11.3828.3828

Published: 2008

Journal Articles

Prognostic Significance of Tissue Necrosis Factor-Alpha in Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes.

Apostolia-Maria Tsimberidou, MD, PhD, Elihu Estey, MD, Maher Albitar, MD, Sijin Wen, MS, Mark Brandt, BS, Sherry Pierce, RN, Hagop Kantarjian, MD, Razelle Kurzrock, MD

Blood (2007) 110 (11): 4263.

https://doi.org/10.1182/blood.V110.11.4263.4263

Published: 2007

Journal Articles

All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (As 2 O 3 ) Combination Therapy Induces High Rates of Durable Molecular Remission in Newly Diagnosed Acute Promyelocytic Leukemia (APL).

Apostolia-Maria Tsimberidou, MD, PhD, Hagop Kantarjian, MD, Susan O’Brien, MD, Guillermo Garcia-Manero, MD, Charles Koller, MD, Daniel Jones, MD, Sherry Pierce, RN, Mark Brandt, BA, Michael Keating, MB, BS, Estey Estey, MD

Blood (2007) 110 (11): 1834.

https://doi.org/10.1182/blood.V110.11.1834.1834

Published: 2007

Journal Articles

Exclusion from Acute Myeloid Leukemia (AML) Clinical Trials of Patients Unlikely To Respond.

Apostolia-Maria Tsimberidou, MD, PhD, Hagop M. Kantarjian, MD, Stefan Faderl, MD, Emil J. Freireich, MD, Elihu Estey, MD

Blood (2007) 110 (11): 2867.

https://doi.org/10.1182/blood.V110.11.2867.2867

Published: 2007

Journal Articles

The Prognostic Significance of 11q Deletion Detected by Fluorescence In Situ Hybridization (FISH) in Untreated Chronic Lymphocytic Leukemia (CLL): The MDACC Experience.

Apostolia-Maria Tsimberidou, MD, PhD, Constantine Tam, MBBS, William G. Wierda, MD, PhD, Susan O’Brien, MD, Susan Lerner, MS, Hagop M. Kantarjian, MD, Michael J. Keating, MBBS

Blood (2007) 110 (11): 2078.

https://doi.org/10.1182/blood.V110.11.2078.2078

Published: 2007

Journal Articles

Other Malignancies in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Analysis of 2083 Patients.

Apostolia-Maria Tsimberidou, MD, PhD, Susan O’Brien, M.D., Peter McLaughlin, M.D., Sijin Wen, M.S., William Wierda, M.D., Ph.D., Hagop M. Kantarjian, M.D., John Manning, M.D., Susan Lerner, M.S., Mark Hess, B.B.A., Emil J. Freireich, M.D., Michael J. Keating, M.D.

Blood (2006) 108 (11): 2790.

https://doi.org/10.1182/blood.V108.11.2790.2790

Published: 2006

Journal Articles

A Prognostic Score for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Analysis of 2189 Patients.

Apostolia-Maria Tsimberidou, MD, PhD, Peter McLaughlin, M.D., Susan O’Brien, M.D., Sijin Wen, M.S., William G. Wierda, M.D., Ph.D., John Manning, M.D., Susan Lerner, M.S., Mark A. Hess, Hagop Kantarjian, M.D., Emil J. Freireich, M.D., Michael J. Keating, M.D.

Blood (2006) 108 (11): 2783.

https://doi.org/10.1182/blood.V108.11.2783.2783

Published: 2006

Journal Articles

Combination of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Richter’s Syndrome and Fludarabine-Refractory Chronic Lymphocytic Leukemia.

Apostolia-Maria Tsimberidou, MD, PhD, William G. Wierda, M.D., Ph.D., Susan O’Brien, M.D., William W. Plunkett, M.D., Thomas J. Kipps, M.D., Jennifer R. Brown, M.D., Ph.D, Susan Lerner, M.S., Hagop Kantarjian, M.D., Michael J. Keating, M.D.

Blood (2006) 108 (11): 2825.

https://doi.org/10.1182/blood.V108.11.2825.2825

Published: 2006

Journal Articles

Genomic Aberrations in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma by Absolute Lymphocyte Count: Analysis of 1694 Patients.

Apostolia-Maria Tsimberidou, MD, PhD, Peter McLaughlin, M.D., Susan O’Brien, M.D., Sijin Wen, M.S., William G. Wierda, M.D., Ph.D., John T. Manning, M.D., Lynne V. Abruzzo, M.D., Ph.D., Susan Lerner, M.S., Mark A. Hess, B.B.A., Hagop M. Kantarjian, M.D., Emil J. Freireich, M.D., Michael J. Keating, M.D.

Blood (2006) 108 (11): 4958.

https://doi.org/10.1182/blood.V108.11.4958.4958

Published: 2006

Journal Articles

Prognostic Significance of β-2 Microglobulin Levels in Acute Myeloid Leukemia: Analysis of 1293 Patients.

Apostolia-Maria Tsimberidou, MD, PhD, Hagop M. Kantarjian, M.D., Michael J. Keating, M.D., Susan O’Brien, M.D., Sijin Wen, M.S., Jorge Cortes, M.D., Francis Giles, M.D., Charles Asa Koller, M.D., Guillermo Garcia-Manero, M.D., Sherry Pierce, B.S.N., Mark Brandt, Emil J. Freireich, M.D., Elihu H. Estey, M.D.

Blood (2006) 108 (11): 802.

https://doi.org/10.1182/blood.V108.11.802.802

Published: 2006

Journal Articles

Granulocytic Sarcoma (GS) Is Associated with Event-Free Survival Superior to That of Acute Myeloid Leukemia (AML).

Apostolia-Maria Tsimberidou, MD, PhD, Michael J. Keating, M.D., Hagop M. Kantarjian, M.D., Susan O’Brien, M.D., Jorge Cortes, M.D., Charles Koller, M.D., BA, Francis Giles, M.D., Sherry Pierce, BSN, BA, Mark Brandt, Miloslav Beran, M.D., Ph.D., Elihu Estey, M.D.

Blood (2006) 108 (11): 2008.

https://doi.org/10.1182/blood.V108.11.2008.2008

Published: 2006

Journal Articles

Comparison of Small Lymphocytic Lymphoma with Chronic Lymphocytic Leukemia The M.D Anderson Cancer Center Experience.

Apostolia-Maria Tsimberidou, MD, PhD, Michael J. Keating, MD, Peter McLaughlin, MD, Susan O’Brien, MD, BA, William Wierda, MD, PhD, BS, Alessandra Ferrajoli, MD, John Manning, MD, BA, Hagop Kantarjian, MD

Blood (2005) 106 (11): 921.

https://doi.org/10.1182/blood.V106.11.921.921

Published: 2005

Journal Articles

Outcomes in Patients with Splenic Marginal Zone Lymphoma or Marginal Zone Leukemia/Lymphoma Treated with Immunotherapy, Chemoimmunotherapy, or Chemotherapy.

Apostolia-Maria Tsimberidou, MD, PhD, Daniel Catovsky, MD, Ellen Schlette, MD, Susan O’Brien, MD, BA, Hagop Kantarjian, MD, William G. Wierda, MD, PhD, Sijin Wen, MS, Susan Lerner, MS, BA, Michael J. Keating, MD

Blood (2005) 106 (11): 922.

https://doi.org/10.1182/blood.V106.11.922.922

Published: 2005

Journal Articles

Epstein-Barr Virus in Patients with Chronic Lymphocytic Leukemia.

Apostolia-Maria Tsimberidou, MD, PhD, Michael J. Keating, MD, Carlos Bueso-Ramos, MD, PhD, Razelle Kurzrock, MD, FACP

Blood (2005) 106 (11): 2113.

https://doi.org/10.1182/blood.V106.11.2113.2113

Published: 2005

Journal Articles

Clinical Outcomes and Prognostic Factors in Patients with Richter’s Syndrome Treated with Chemotherapy and/or Immunotherapy with or without Stem Cell Transplantation.

Apostolia-Maria Tsimberidou, MD, PhD, Susan O’Brien, MD, BA, Issa Khouri, MD, BS, Francis J. Giles, MD, Hagop M. Kantarjian, MD, Sijin Wen, MS, Susan C. Smith, BS, Susan Lerner, MS, BA, Emil J. Freireich, MD, BS, Michael J. Keating, MD

Blood (2005) 106 (11): 2097.

https://doi.org/10.1182/blood.V106.11.2097.2097

Published: 2005

Journal Articles

Transformation of Chronic Lymphocytic Leukemia into Hodgkin’s Disease The M D Anderson Cancer Center Experience.

Apostolia-Maria Tsimberidou, MD, PhD, Susan O’Brien, MD, BA, Hagop Kantarjian, MD, Charles Koller, MD, BA, Fredrick Hagemeister, MD, BA, Luis Fayad, MD, Susan Lerner, MS, BA, Michael J. Keating, MD

Blood (2005) 106 (11): 976.

https://doi.org/10.1182/blood.V106.11.976.976

Published: 2005

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Phase I-II Study of Fludarabine, Cytarabine and Oxaliplatin In Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Results of a Phase I-II Clinical Trial of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab (OFAR) Combination Therapy In Patients with Aggressive, Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Richter Syndrome (RS)

Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy Induces High Response Rates in Agressive Chronic Lymphocytic Leukemia (CLL) and Richter's Syndrome (RS).

Pediatric Therapy-Related Myelodysplastic Syndrome/Acute Myeloid Leukemia: The M. D. Anderson Cancer Center Experience

Clinical Outcomes and Factors Predicting Development of Venous Thromboembolic Complications in Patients with Advanced Refractory Cancer in a Phase I Clinic: The M. D. Anderson Cancer Center Experience

Prognostic Significance of Tissue Necrosis Factor-Alpha in Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes.

All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (As 2 O 3 ) Combination Therapy Induces High Rates of Durable Molecular Remission in Newly Diagnosed Acute Promyelocytic Leukemia (APL).

Exclusion from Acute Myeloid Leukemia (AML) Clinical Trials of Patients Unlikely To Respond.

The Prognostic Significance of 11q Deletion Detected by Fluorescence In Situ Hybridization (FISH) in Untreated Chronic Lymphocytic Leukemia (CLL): The MDACC Experience.

Other Malignancies in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Analysis of 2083 Patients.

A Prognostic Score for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Analysis of 2189 Patients.

Combination of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Richter’s Syndrome and Fludarabine-Refractory Chronic Lymphocytic Leukemia.

Genomic Aberrations in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma by Absolute Lymphocyte Count: Analysis of 1694 Patients.

Prognostic Significance of β-2 Microglobulin Levels in Acute Myeloid Leukemia: Analysis of 1293 Patients.

Granulocytic Sarcoma (GS) Is Associated with Event-Free Survival Superior to That of Acute Myeloid Leukemia (AML).

Comparison of Small Lymphocytic Lymphoma with Chronic Lymphocytic Leukemia The M.D Anderson Cancer Center Experience.

Outcomes in Patients with Splenic Marginal Zone Lymphoma or Marginal Zone Leukemia/Lymphoma Treated with Immunotherapy, Chemoimmunotherapy, or Chemotherapy.

Epstein-Barr Virus in Patients with Chronic Lymphocytic Leukemia.

Clinical Outcomes and Prognostic Factors in Patients with Richter’s Syndrome Treated with Chemotherapy and/or Immunotherapy with or without Stem Cell Transplantation.

Transformation of Chronic Lymphocytic Leukemia into Hodgkin’s Disease The M D Anderson Cancer Center Experience.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only